Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

被引：0

作者：

Andrea Sacconi

Paola Muti

Claudio Pulito

Giulia Urbani

Matteo Allegretti

Raul Pellini

Nikolay Mehterov

Uri Ben-David

Sabrina Strano

Paolo Bossi

Giovanni Blandino

机构：

[1] Clinical Trial Center,Department of Biomedical

[2] Biostatistics and Bioinformatics,Translational Oncology Research Unit

[3] IRCCS Regina Elena National Cancer Institute,Department of Medical Biology

[4] Surgical Science and Oral Health,Research Institute

[5] Milan University,Department of Human Molecular Genetics and Biochemistry

[6] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Department of Biomedical Sciences

[7] Maxillo-Facial Surgery and Dental Unit,undefined

[8] IRCCS Regina Elena National Cancer Institute,undefined

[9] Otolaryngology Head and Neck Surgery Unit,undefined

[10] IRCCS Regina Elena National Cancer Institute,undefined

[11] Medical University-Plovdiv,undefined

[12] Medical University-Plovdiv,undefined

[13] Faculty of Medicine,undefined

[14] Tel Aviv University,undefined

[15] SAFU Unit,undefined

[16] IRCCS Regina Elena National Cancer Institute,undefined

[17] Humanitas University,undefined

[18] IRCCS Humanitas Research Hospital,undefined

来源：

Molecular Cancer | / 22卷

关键词：

HNSCC; Immunotherapy; Immune checkpoint inhibitor; p53; PDL1; c-MYC; PI3K;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Truncating TP53 mutations have prognostic significance in head and neck squamous cell carcinoma
van der Plas, Marlon
Brakenhoff, Ruud H.
Kuik, Dirk J.
Buijze, Marijke
Bloemena, Elisabeth
Snijders, Peter Jf
Leemans, C. Rene
Braakhuis, Boudewijn Jm
CANCER RESEARCH, 2011, 71
[42] TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma
Gallina, F. T.
Marinelli, D.
Taje, R.
Melis, E.
Visca, P.
Buglioni, S.
Cappuzzo, F.
Najmeh, S.
Cools-Lartigue, J.
Ferri, L.
Broet, S. Camilleri
Fiset, P. O.
Spicer, J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S553 - S554
[43] Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer
Manoharan, Vahinipriya
Karunanayake, Eric Hamilton
Tennekoon, Kamani Hemamala
De Silva, Sumadee
De Silva, Kanishka
Angunawela, Preethika
Lunec, John
MOLECULAR MEDICINE REPORTS, 2019, 19 (04) : 2781 - 2791
[44] Co-mutations of KRAS/BRAF and TP53 or the high tumor mutation burden to predict survival in patients with biliary tract carcinoma.
Guo, Lingling
Kou, Xiaoxia
Song, Panpan
Zhang, Xiaoyu
Zhang, Hongjuan
Qiu, Jinrong
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[45] Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
Liu, Yutao
Xu, Fang
Wang, Yubo
Wu, Qingchen
Wang, Buhai
Yao, Yanwen
Zhang, Yu
Han-Zhang, Han
Ye, Junyi
Zhang, Lu
Mao, Xinru
Zhang, Zhe
Liu, Jing
Zhu, Liangjun
Guo, Renhua
ONCOLOGY LETTERS, 2019, 18 (03) : 3159 - 3169
[46] TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients
Pandey, Ritu
Johnson, Nathan
Cooke, Laurence
Johnson, Benny
Chen, Yuliang
Pandey, Manjari
Chandler, Jason
Mahadevan, Daruka
CANCERS, 2021, 13 (04) : 1 - 21
[47] KRAS, BRAF and TP53 mutations in Romanian colorectal cancer patients
Murarasu, Daniela
Puiu, Liliana
Mihalcea, Corina
Cinca, Sabin
Simion, Laurentiu
JOURNAL OF BIOTECHNOLOGY, 2016, 231 : S92 - S92
[48] Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Alsner, J
Yilmaz, M
Guldberg, P
Hansen, LL
Overgaard, J
CLINICAL CANCER RESEARCH, 2000, 6 (10) : 3923 - 3931
[49] Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
J Alsner
M Yilmaz
P Guldberg
LL Hansen
J Overgaard
Breast Cancer Research, 2 (Suppl 1)
[50] Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma
Liu, Di-Han
Zhao, Ze-Rui
Lin, Yao-Bin
Zhou, Wen-Jie
Hou, Jing-Yu
Ye, Zheng-Hao
Long, Hao
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1934 - 1941

← 1 2 3 4 5 →